Mutation of key FcγR binding residues abrogates this interaction without affecting CAR function and such a modification may be necessary for effective anti-tumour responses in vivo whilst retaining the additional advantage of Fc as a spacer–including detection of CAR T cells with with polyclonal anti-Fc antibodies. The gene discussed is FCGR2A; the disease is neoplasm.